Journal article
Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran
Abstract
Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation. The RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy [with Dabigatran Etexilate]) study showed that dabigatran given at a dose of 110 mg twice a day (bid) was associated with rates of stroke and systemic embolism that were similar to …
Authors
Weimar C; Hohnloser SH; Eikelboom JW; Diener H-C
Journal
Current Neurology and Neuroscience Reports, Vol. 12, No. 1, pp. 17–23
Publisher
Springer Nature
Publication Date
February 2012
DOI
10.1007/s11910-011-0229-4
ISSN
1528-4042